USA Leading a New Frontier in Gene Therapy Market
"Citing the potential of gene therapy in treating different chronic and life-threatening diseases, US companies rush to develop transformative gene therapies", says RNCOS.
According to RNCOS’ new research report "Global & US Gene Therapy Market Forecast to 2020", the US represents 59% of the global market for gene therapy. Being the largest market, the region is set to witness several developments in near future. RNCOS’ analysis has revealed that the market is likely to expand in the next five years (2015-2020) amidst the increasing prevalence of genetic and neurological disorders, growing awareness, technological advancements, and initiatives taken by the federal governments. The region has also been witnessing entry of new products, new players, and collaborations, which are driving the market.
Beyond that, there is a growing pipeline rapidly coming forward. The country, comprising 51 states, conducts the majority of the gene therapy clinical trials in the world. The maximum numbers of developments are occurring in the US, with 1,386 trials in the last decade. With more than 60% of the total gene therapy trials occurring in the US, there is still lower number of approved gene therapies in the United States. This is evident due to the country’s stringent regulatory laws for approval of such therapies. Nonetheless, the rising number of developments in early or late stages will expectedly introduce new therapies in the future.
Research Analysis and Highlights
The report is spread in over 209 pages and provides an in-depth research and rational analysis of the Global & US Gene Therapy Market. An effective analysis of the key therapeutic areas has been included in the report which provides a comprehensive overview of various diseases in which the gene therapy is used, along with the current and future market size of gene therapy for particular disease and its geographical break up. Furthermore, the chapter also provides details regarding the various aspects of the clinical trials in the different gene therapy application by phases, vector types, etc. The report also provides the sales of major commercialized gene therapy products, and the list of the products in clinical/pre-clinical research along with their clinical phases. A brief overview of the key geographies in the gene therapy segment and the regulatory scenario governing the industry has also been included in the study to present a balanced outlook. The report covers how major trends and drivers will propel the industry’s growth. With a view to understand the competitive landscape, the profiles of key market players are included in the report to present a complete picture of the global gene therapy market.
Some of the key highlights of the report include the following:
• Strategic Collaborations, Acquisitions, & Funding & Investments advancing gene therapy research and development
• US showing dynamic research and development for gene therapy.
• Clinical Trial Assessment & Pipeline Analysis
• Regulatory Landscape & Reimbursement Scenario
For FREE SAMPLE of this report visit: http://rncos.viewpage.co/Global--US-Gene-Therapy-Market-Forecast-to-2020
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.
by: Shushmul Maheshwari